MX2011008305A - Compuestos de piridazinona. - Google Patents

Compuestos de piridazinona.

Info

Publication number
MX2011008305A
MX2011008305A MX2011008305A MX2011008305A MX2011008305A MX 2011008305 A MX2011008305 A MX 2011008305A MX 2011008305 A MX2011008305 A MX 2011008305A MX 2011008305 A MX2011008305 A MX 2011008305A MX 2011008305 A MX2011008305 A MX 2011008305A
Authority
MX
Mexico
Prior art keywords
ring
substituent
substituted
sub
compound
Prior art date
Application number
MX2011008305A
Other languages
English (en)
Inventor
Takahiko Taniguchi
Akira Kawada
Mitsuyo Kondo
John F Quinn
Kunitomojun
Masato Yoshikawa
Makoto Fushimi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MX2011008305A publication Critical patent/MX2011008305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

La presente invención provee un compuesto que tiene el efecto de inhibición de PDE, y que es útil como un medicamento para prevenir o tratar la esquizofrenia o así sucesivamente. Un compuesto de la fórmula (I0), en donde R1 representa un sustituyente; R2 representa un átomo de hidrógeno, o un sustituyente; R3 representa un átomo de hidrógeno, o un sustituyente; el Anillo A representa un anillo aromático que puede estar sustituido, y el Anillo B representa un anillo heteroaromático de 5 miembros que puede estar sustituido, o una sal del mismo. (ver fórmula (I0)).
MX2011008305A 2009-02-05 2010-02-04 Compuestos de piridazinona. MX2011008305A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20220709P 2009-02-05 2009-02-05
US21392709P 2009-07-30 2009-07-30
PCT/US2010/000307 WO2010090737A1 (en) 2009-02-05 2010-02-04 Pyridazinone compounds

Publications (1)

Publication Number Publication Date
MX2011008305A true MX2011008305A (es) 2012-08-15

Family

ID=42398214

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008305A MX2011008305A (es) 2009-02-05 2010-02-04 Compuestos de piridazinona.

Country Status (38)

Country Link
US (7) US8354411B2 (es)
EP (2) EP3006031A1 (es)
JP (1) JP5659166B2 (es)
KR (1) KR101730665B1 (es)
CN (1) CN102365020B (es)
AR (1) AR075238A1 (es)
AU (1) AU2010211050B2 (es)
BR (1) BRPI1008498B8 (es)
CA (1) CA2751565C (es)
CO (1) CO6410258A2 (es)
CR (1) CR20110440A (es)
DK (1) DK2393360T3 (es)
DO (1) DOP2011000254A (es)
EA (1) EA020690B1 (es)
EC (1) ECSP11011305A (es)
ES (1) ES2561181T3 (es)
GE (1) GEP20146004B (es)
HK (1) HK1164642A1 (es)
HR (1) HRP20160065T1 (es)
HU (1) HUE027478T2 (es)
IL (1) IL214137A (es)
JO (1) JO3114B1 (es)
MA (1) MA33072B1 (es)
ME (1) ME02337B (es)
MX (1) MX2011008305A (es)
MY (1) MY170610A (es)
NZ (1) NZ594851A (es)
PE (1) PE20110991A1 (es)
PL (1) PL2393360T3 (es)
RS (1) RS54504B1 (es)
SG (1) SG173175A1 (es)
SI (1) SI2393360T1 (es)
SM (1) SMT201600008B (es)
TN (1) TN2011000362A1 (es)
TW (1) TWI457333B (es)
UY (1) UY32417A (es)
WO (1) WO2010090737A1 (es)
ZA (1) ZA201106074B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200924774A (en) * 2007-10-26 2009-06-16 Astrazeneca Ab Fused pyrrolidine 1,2,4-triazole derivatives as modulators of mGluR5
US8304413B2 (en) * 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
ES2561181T3 (es) * 2009-02-05 2016-02-24 Takeda Pharmaceutical Company Limited Compuestos de piridazinona
MX341446B (es) 2010-06-24 2016-08-19 Takeda Pharmaceuticals Co Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
WO2012009194A1 (en) * 2010-07-12 2012-01-19 Merck Sharp & Dohme Corp. Tyrosine kinase inhibitors
JP5785548B2 (ja) * 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
JP5800813B2 (ja) 2010-08-04 2015-10-28 武田薬品工業株式会社 複素環化合物
JP5760085B2 (ja) 2010-08-04 2015-08-05 武田薬品工業株式会社 縮合複素環化合物
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a
JP2013234123A (ja) * 2010-09-03 2013-11-21 Taisho Pharmaceutical Co Ltd ３−ピラゾリル−２−ピリドン誘導体
SG192839A1 (en) 2011-02-18 2013-09-30 Allergan Inc Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
WO2012124782A1 (ja) 2011-03-16 2012-09-20 武田薬品工業株式会社 縮合複素環化合物
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
ES2663370T3 (es) 2011-08-22 2018-04-12 Takeda Pharmaceutical Company Limited Compuestos radiomarcados y su uso como radiotrazadores para imagenología cuantitativa de la fosfodiesterasa (PDE10A) en mamíferos
JP6169492B2 (ja) 2011-11-15 2017-07-26 武田薬品工業株式会社 ジヒドロキシ芳香族へテロ環化合物
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
JP6364420B2 (ja) 2013-02-21 2018-07-25 武田薬品工業株式会社 ピリダジノン化合物の製造方法
WO2014142322A1 (ja) 2013-03-15 2014-09-18 第一三共株式会社 ベンゾチオフェン誘導体
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
ES2724581T3 (es) * 2013-09-12 2019-09-12 Janssen Biopharma Inc Compuestos de piridazinona y usos de los mismos
ES2821394T3 (es) 2013-09-12 2021-04-26 Alios Biopharma Inc Compuestos de 7,8-dihidro-3H-pirazino[1,2-b]piridazin-3,5(6H)-diona y usos de los mismos
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
ES2544869B2 (es) * 2014-03-04 2016-01-18 Universidade De Vigo Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa
US10231929B2 (en) 2014-03-18 2019-03-19 Takeda Pharmaceutical Company Limited Solid dispersion
WO2015153683A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CA2979216A1 (en) 2015-03-11 2016-09-15 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2017107754A1 (zh) 2015-12-22 2017-06-29 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物、其制备方法及其在医药上的应用
WO2019161179A1 (en) 2018-02-15 2019-08-22 Ovid Therapeutics Inc. Methods of treating developmental syndromes with pde10a inhibitors
CN108498868B (zh) * 2018-04-03 2020-09-15 北京大学口腔医学院 具有细胞外基质电学拓扑特征的带电复合膜及其制备方法
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
WO2019241787A1 (en) * 2018-06-15 2019-12-19 The Regents Of The University Of Colorado A Body Corporate Novel cyclic gmp-amp synthase (cgas) inhibitors and their method of use
WO2020065583A1 (en) * 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
MX2019008440A (es) 2019-07-15 2021-01-18 Dva Farma Mexicana S A De C V Composiciones de recubrimientos en pelicula para tabletas con brillantez incrementada, procedimiento de preparacion y aplicacion.
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0011693A1 (de) * 1978-10-03 1980-06-11 Ciba-Geigy Ag Neue N-(trifluormethansulfonylaminophenyl)-substituierte N-Heterocyclen, ihre Herstellung, sie enthaltende Mittel und ihre Verwendung zur Beeinflussung des Pflanzenwachstums
FR2648135B1 (fr) * 1989-06-07 1991-09-27 Pf Medicament Derives de phenyl-1-dihydro-1,4 amino-3 oxo-4 pyridazines, leur preparation et leur application en therapeutique
GB9506382D0 (en) * 1995-03-29 1995-05-17 Boots Co Plc Pharmaceutical compositions
WO2000009488A1 (fr) 1998-08-14 2000-02-24 Nihon Nohyaku Co., Ltd. Derives de pyridazinone
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
BRPI0511854A (pt) 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
EP1769092A4 (en) 2004-06-29 2008-08-06 Europ Nickel Plc IMPROVED LIXIVIATION OF BASE METALS
JP4302762B2 (ja) 2005-01-07 2009-07-29 ファイザー・プロダクツ・インク 複素環式芳香族キノリン化合物およびｐｄｅ１０阻害剤としてのその使用
US7763617B2 (en) 2005-03-07 2010-07-27 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridine-4-yl pyridazinone derivatives and addition salts thereof, and PDE inhibitors comprising the same derivatives or salts as active ingredient
JP2009541481A (ja) 2006-06-26 2009-11-26 ファイザー・プロダクツ・インク Ｐｄｅ１０阻害剤としての三環式ヘテロアリール化合物
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010000020A1 (en) 2008-06-30 2010-01-07 Cathrx Ltd A catheter
TWI396689B (zh) 2008-11-14 2013-05-21 Amgen Inc 作為磷酸二酯酶１０抑制劑之吡衍生物
TW201030001A (en) 2008-11-14 2010-08-16 Amgen Inc Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors
CA2744489C (en) * 2008-12-04 2015-06-23 F.Hoffmann-La Roche Ag Pyridazinone derivatives
ES2561181T3 (es) 2009-02-05 2016-02-24 Takeda Pharmaceutical Company Limited Compuestos de piridazinona
US9187455B2 (en) * 2009-02-23 2015-11-17 Hoffmann-La Roche Inc. Substituted pyridazines as PDE10A inhibitors
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
JP5785548B2 (ja) * 2010-08-04 2015-09-30 武田薬品工業株式会社 縮合複素環化合物
EP2604597B1 (en) * 2010-08-10 2017-01-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof inhibitor of phosphodiesterase 10a

Also Published As

Publication number Publication date
HUE027478T2 (en) 2016-09-28
US20120277431A1 (en) 2012-11-01
TN2011000362A1 (en) 2013-03-27
ECSP11011305A (es) 2011-11-30
CA2751565A1 (en) 2010-08-12
EA201171004A1 (ru) 2012-03-30
NZ594851A (en) 2013-10-25
DK2393360T3 (en) 2016-02-01
CO6410258A2 (es) 2012-03-30
KR101730665B1 (ko) 2017-04-26
DOP2011000254A (es) 2011-09-30
SG173175A1 (en) 2011-09-29
AU2010211050B2 (en) 2016-05-12
SMT201600008B (it) 2016-02-25
CR20110440A (es) 2012-02-13
US20100197651A1 (en) 2010-08-05
AU2010211050A2 (en) 2011-10-06
US20120277430A1 (en) 2012-11-01
PE20110991A1 (es) 2012-02-06
US8778944B2 (en) 2014-07-15
UY32417A (es) 2010-08-31
US8916566B2 (en) 2014-12-23
US8435995B2 (en) 2013-05-07
US20120277204A1 (en) 2012-11-01
JP2012516890A (ja) 2012-07-26
AR075238A1 (es) 2011-03-16
MA33072B1 (fr) 2012-02-01
CN102365020B (zh) 2014-07-30
EP3006031A1 (en) 2016-04-13
ZA201106074B (en) 2012-10-31
EP2393360B1 (en) 2015-11-04
HK1164642A1 (zh) 2012-09-28
EP2393360A4 (en) 2012-08-15
KR20110120931A (ko) 2011-11-04
IL214137A (en) 2015-07-30
US9550756B2 (en) 2017-01-24
WO2010090737A1 (en) 2010-08-12
CN102365020A (zh) 2012-02-29
JO3114B1 (ar) 2017-09-20
US8513251B2 (en) 2013-08-20
ES2561181T3 (es) 2016-02-24
BRPI1008498B8 (pt) 2021-05-25
EP2393360A1 (en) 2011-12-14
TW201036958A (en) 2010-10-16
CA2751565C (en) 2017-05-16
JP5659166B2 (ja) 2015-01-28
MY170610A (en) 2019-08-20
RS54504B1 (en) 2016-06-30
BRPI1008498A2 (pt) 2015-08-25
SI2393360T1 (sl) 2016-02-29
BRPI1008498B1 (pt) 2020-02-11
US20120028951A1 (en) 2012-02-02
US20170114044A1 (en) 2017-04-27
GEP20146004B (en) 2014-01-10
US8354411B2 (en) 2013-01-15
IL214137A0 (en) 2011-08-31
AU2010211050A1 (en) 2011-09-08
TWI457333B (zh) 2014-10-21
US20150099757A1 (en) 2015-04-09
HRP20160065T1 (hr) 2016-02-12
EA020690B1 (ru) 2015-01-30
ME02337B (me) 2016-06-20
PL2393360T3 (pl) 2016-04-29

Similar Documents

Publication Publication Date Title
MX2011008305A (es) Compuestos de piridazinona.
MX341446B (es) Compuestos heterociclicos fusionados como inhibidores de fosfodiesterasas (pdes).
JO2791B1 (en) Acid secretion inhibitor
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
TNSN07348A1 (en) Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor
JO2732B1 (en) Organic compounds
MY152972A (en) Azabicyclo compound and salt thereof
MX2010009736A (es) Compuesto heterociclico.
IN2012DN00770A (es)
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
TN2011000422A1 (en) Benzofuran derivatives
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
MY169179A (en) Novel piperidine compound or salt thereof
WO2009038064A1 (ja) Ｉ型１１βヒドロキシステロイド脱水素酵素阻害活性を有する複素環誘導体
WO2009054439A1 (ja) Pai-1産生抑制剤
JO2741B1 (en) Spiro-cyclic nitroblast as protease inhibitors
WO2008051533A3 (en) Benzimidazole compounds
MX2010001566A (es) Derivado de aminopirazolamida.
EP2602254A4 (en) HETEROCYCLIC COMPOUND
NZ611169A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
IN2012DN00768A (es)
WO2009041559A1 (ja) インダゾールアクリル酸アミド化合物
MX2009004982A (es) Derivados heterociclicos como inhibidores cetp.
UA102539C2 (ru) Производные оксадиазола, активные в отношении сфингозин-1-фосфата (s1p)

Legal Events

Date Code Title Description
FG Grant or registration